{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:25:16Z","timestamp":1794072316888,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>BCL-2 protein overexpression, common in B-cell acute lymphoblastic leukemia (B-ALL), including the Philadelphia chromosome (Ph)-like subtype, mediates leukemic cell survival. We treated 24 patients with 14 days of BCL-2 inhibitor, venetoclax, 400 mg daily (dose level 1) during induction and consolidation cycles combined with the CALGB 10403 regimen in newly diagnosed adults with Ph-negative B-ALL. Median age was 31 years (range: 18-53), 92% were Hispanic, and 12 (50%) patients had Ph-like ALL. No dose-limiting toxicity occurred in the phase 1 part. Median times to neutrophil and platelet count recovery were 20 and 21 days from start of induction, respectively. The most common grade \u22653 treatment-related adverse events were leukopenia (96%), neutropenia (83%), anemia (83%), thrombocytopenia (79%), lymphopenia (71%), hyperbilirubinemia (38%), and elevated ALT (33%). One patient with non-Ph-like ALL died from asparaginase-associated pancreatitis, and 23 (96%) patients achieved complete remission (CR) or CR with incomplete count recovery (CRi) following induction with or without extended induction phase. Of the 22 patients who started consolidation, 20 (91%) achieved negative minimal residual disease status (MRD-) (&lt;0.01%) CR\/CRi by flow cytometry. Of 12 patients with Ph-like B-ALL, 11 achieved MRDstatus post consolidation, with only one patient having persistent MRD at 0.01%. At diagnosis, Ph-like B-ALL cases had a trend toward a greater BCL-2-dependency compared to non-Ph-like (P=0.06). The addition of venetoclax to a pediatric-inspired regimen was safe in adults with B-ALL, leading to encouraging MRD- rate post consolidation in high-risk B-ALL, including the Ph-like subtype (clinicaltrials.gov 05157971).<\/jats:p>","DOI":"10.3324\/haematol.2024.286427","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T03:17:10Z","timestamp":1730949430000},"page":"1105-1114","source":"Crossref","is-referenced-by-count":7,"title":["Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"Saygin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diren Arda","family":"Karaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Pourhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Blackmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Otoukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Tinajero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ghoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"74883","doi-asserted-by":"crossref","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol. 2023; 41(36):5579-5591.","DOI":"10.1200\/JCO.23.01286"},{"key":"74884","doi-asserted-by":"crossref","unstructured":"Sasaki K, Jabbour E, Short NJ. Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol. 2021; 96(6):650-658.","DOI":"10.1002\/ajh.26156"},{"key":"74885","doi-asserted-by":"crossref","unstructured":"Stock W, Luger SM, Advani AS. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 134(13):1548-1559.","DOI":"10.1182\/blood.2019002613"},{"key":"74886","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018; 32(3):606-615.","DOI":"10.1038\/leu.2017.265"},{"key":"74887","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015; 29(3):526-534.","DOI":"10.1038\/leu.2014.229"},{"key":"74888","doi-asserted-by":"crossref","unstructured":"Geyer MB, Ritchie EK, Rao AV. Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021; 106(8):2086-2094.","DOI":"10.3324\/haematol.2020.251686"},{"key":"74889","doi-asserted-by":"crossref","unstructured":"Douer D, Aldoss I, Lunning MA. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):905-911.","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"74890","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Messina M, Della Starza I. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica. 2021; 106(6):1559-1568.","DOI":"10.3324\/haematol.2020.247973"},{"key":"74891","doi-asserted-by":"crossref","unstructured":"Roberts KG, Gu Z, Payne-Turner D. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017; 35(4):394-401.","DOI":"10.1200\/JCO.2016.69.0073"},{"key":"74892","doi-asserted-by":"crossref","unstructured":"Jain N, Roberts KG, Jabbour E. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017; 129(5):572-581.","DOI":"10.1182\/blood-2016-07-726588"},{"key":"74893","doi-asserted-by":"crossref","unstructured":"Roberts KG, Li Y, Payne-Turner D. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-1015.","DOI":"10.1056\/NEJMoa1403088"},{"key":"74894","doi-asserted-by":"crossref","unstructured":"Tasian SK, Teachey DT, Li Y. Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017; 129(2):177-187.","DOI":"10.1182\/blood-2016-05-707653"},{"key":"74895","doi-asserted-by":"crossref","unstructured":"Salzer WL, Burke MJ, Devidas M. Feasibility and outcome of post-induction therapy incorporating dasatinib for patients with newly diagnosed ABL-class fusion B-lymphoblastic leukemia (ABL-class Fusion BALL): Children\u2019s Oncology Group AALL1131. Blood. 2023; 142(Suppl 1):961.","DOI":"10.1182\/blood-2023-190495"},{"key":"74896","doi-asserted-by":"crossref","unstructured":"Tasian SK, Hunter DS, Chen IML. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (AALL1521\/ INCB18424-269): biologic characteristics and minimal residual disease response of patients with non-rearranged JAK pathway alterations. Blood. 2022; 140(Suppl 1):6117-6118.","DOI":"10.1182\/blood-2022-164699"},{"key":"74897","doi-asserted-by":"crossref","unstructured":"Litzow MR, Sun ZX, Paietta E. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network trial. Blood. 2022; 140(Suppl 2):LBA-1.","DOI":"10.1182\/blood-2022-171751"},{"key":"74898","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Della Starza I, Santoro A. Sequential chemotherapy and blinatumomab to improve minimal residual disease in adult Ph- B-lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 trial. Blood. 2023; 142:826.","DOI":"10.1182\/blood-2023-174973"},{"key":"74899","doi-asserted-by":"crossref","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021; 11(6):1440-1453.","DOI":"10.1158\/2159-8290.CD-20-1465"},{"key":"74900","doi-asserted-by":"crossref","unstructured":"Short NJ, Jabbour E, Jain N. A phase 1\/2 study of minihyper-CVD plus venetoclax in patients with relapsed \/ refractory acute lymphoblastic leukemia. Blood Adv. 2024; 8(4):909-915.","DOI":"10.1182\/bloodadvances.2023012231"},{"key":"74901","doi-asserted-by":"crossref","unstructured":"Gokbuget N, Kneba M, Raff T. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120(9):1868-1876.","DOI":"10.1182\/blood-2011-09-377713"},{"key":"74902","doi-asserted-by":"crossref","unstructured":"Bassan R, Spinelli O, Oldani E. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113(18):4153-4162.","DOI":"10.1182\/blood-2008-11-185132"},{"key":"74903","doi-asserted-by":"crossref","unstructured":"Ribera JM, Oriol A, Morgades M. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014; 32(15):1595-1604.","DOI":"10.1200\/JCO.2013.52.2425"},{"key":"74904","doi-asserted-by":"crossref","unstructured":"Aldoss I, Yang D, Tomasian V. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Blood Adv. 2022; 6(17):4936-4948.","DOI":"10.1182\/bloodadvances.2022007597"},{"key":"74905","doi-asserted-by":"crossref","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023; 102(3):541-546.","DOI":"10.1007\/s00277-023-05102-y"},{"key":"74906","doi-asserted-by":"crossref","unstructured":"Karrar O, Abdelmagid M, Rana M. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol. 2024; 99(2):E63-E66.","DOI":"10.1002\/ajh.27180"},{"key":"74907","doi-asserted-by":"crossref","unstructured":"Brown PA, Shah B, Advani A. Acute lymphoblastic leukemia, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(9):1079-1109.","DOI":"10.6004\/jnccn.2021.0042"},{"key":"74908","doi-asserted-by":"crossref","unstructured":"Shimony S, Flamand Y, Valtis YK. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023; 7(18):5234-5245.","DOI":"10.1182\/bloodadvances.2023009976"},{"key":"74909","doi-asserted-by":"crossref","unstructured":"Orgel E, Tucci J, Alhushki W. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014; 124(26):3932-3938.","DOI":"10.1182\/blood-2014-08-595389"},{"key":"74910","doi-asserted-by":"crossref","unstructured":"Aldoss I, Douer D, Behrendt CE. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016; 96(4):375-380.","DOI":"10.1111\/ejh.12600"},{"key":"74911","doi-asserted-by":"crossref","unstructured":"Short NJ, Kantarjian H, Ravandi F. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022; 6(13):4006-4014.","DOI":"10.1182\/bloodadvances.2022007378"},{"key":"74912","doi-asserted-by":"crossref","unstructured":"Wood B, Wu D, Crossley B. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018; 131(12):1350-1359.","DOI":"10.1182\/blood-2017-09-806521"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286427\/77747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286427\/78324","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286427\/77747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:06:57Z","timestamp":1794071217000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286427","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}